Summary
In The Hindu, physicians Enas A. Enas and Basil Varkey responded to Chief Minister V.D. Satheesan's remarks questioning unnecessary angioplasty, which medical organisations had said could undermine public confidence in doctors.
They argue that stents save lives in acute heart attacks and help selected patients with persistent angina. In stable coronary disease, however, the ISCHEMIA trial, published in The New England Journal of Medicine in 2020 with 5,179 patients, found no significant difference in outcomes between an initial invasive strategy and optimal medical therapy at 3.2 years or at five years.
Annual PCI procedures in India rose from about 1,13,000 in 2008 to over 7,26,000 in 2024, while US procedures fell by about 40 per cent between 2003 and 2016. The authors call for scrutiny of incentives and practice patterns instead of either condemning doctors or defending them by reflex.
WHY IT MATTERS FOR UPSC & STATE PCS
A Chief Minister's criticism of unnecessary angioplasty, the medical profession's objection to it and a physicians' evidence-based reply have together raised a core GS4 question: how a doctor should act when institutional incentives reward intervention and the patient cannot judge whether it is needed.
Standard News
The Stable Patient and the Counted Procedure
Imagine you are the cardiologist. Your patient is in his fifties and his condition is stable. He has no heart attack and no chest pain that stops him working. His angiogram shows a narrowing. He looks at you and says: Doctor, do whatever is needed. Your hospital tracks procedure volume and your department's numbers are reviewed every month. Placing the stent is the easy option. The patient expects it, the hospital rewards it and nobody will question you. But the evidence does not support it.
What the
evidence says The ISCHEMIA trial, published in The New England Journal of Medicine in 2020, enrolled 5,179 patients with stable coronary disease and moderate to severe ischemia at 320 sites in 37 countries. Patients were assigned either to an initial invasive strategy or to optimal medical therapy, with revascularisation kept for those who had an acute event or angina.
At a median of 3.2 years and again at five years, there was no significant difference in the main outcome and death rates were similar. A stent treats one narrowing. It does not cure atherosclerosis or remove the risk of a future heart attack.
An angiogram shows anatomy. It does not by itself show that a narrowing needs a stent.
Why both choices cost something Not stenting is not free for you.
The patient may feel under-treated and go to another hospital that will stent him. Your procedure numbers will fall in a hospital that counts them. And if he has a heart attack next year, even one the evidence says a stent would not have prevented, people may say you failed him.
Stenting is not free for him. He takes on the risks of an invasive procedure and its cost, his family pays and his lasting protection still has to come from the medicines and lifestyle changes he needed anyway.
The principle that decides it Non-maleficence comes first.
Do not expose a patient to the risks and costs of a procedure that the best available evidence says will not improve his outcome. Informed consent comes next. Do whatever is needed is not consent. It is trust given to you and that trust is exactly what a fee-for-procedure system can exploit. Professional autonomy means your judgment is free from the hospital's spreadsheet, not that you are free to go along with it.
The decision Do not place the stent today.
Start optimal medical therapy. Explain the ISCHEMIA findings plainly, offer a second opinion and record his informed choice. Tell him stenting remains an option if angina persists and limits his life. Then raise the volume incentive formally, so that the next doctor does not face the same pressure.
You will pay for this decision in lost procedures, in your department's displeasure and possibly in losing this patient to someone less careful. That cost is what it takes to keep the patient's interest first.
Quick Facts
Key numbers & takeaways — revise these first
-
The ISCHEMIA trial was published in The New England Journal of Medicine in 2020.
-
It enrolled 5,179 patients with stable coronary artery disease and moderate to severe ischemia, at 320 sites in 37 countries.
-
At a median follow-up of 3.2 years, it found no significant difference between invasive and conservative strategies and similar all-cause and cardiovascular mortality.
-
At five years, there was still no significant difference.
-
According to the National Interventional Council, annual PCI procedures in India rose from about 1,13,000 in 2008 to over 7,26,000 in 2024.
-
PCI procedures in the US fell by about 40 per cent between 2003 and 2016.
-
Optimal medical therapy includes LDL-cholesterol lowering, antiplatelet treatment, blood-pressure control, diabetes management and lifestyle change.
-
The NMC (Professional Conduct) Regulations, 2023 prohibit unnecessary procedures and the commercial exploitation of patients.
Connect the dots for your UPSC preparation.
Standard news covers the event. Log in to read our comprehensive analysis and uncover the hidden constitutional, structural, and ethical dimensions of this topic:
Both sides of the dilemma fully costed, including the defensive-medicine risk the cardiologist carries if the patient has a later heart attack
Principlism, informed consent and Kant applied to this patient's specific words and why deference is not consent
The St. Joseph Medical Center case and what it shows about institutions that count procedures
The full resolution, from shared decision-making to challenging the incentive structure and an honest account of what the cardiologist gives up
Included in this analysis
Join thousands of aspirants analyzing the news deeply.
Unlock Premium — Rs.699 AnnuallyDon't have an account? Sign up for free